08:52 AM EDT, 09/29/2025 (MT Newswires) -- Abbott Laboratories ( ABT ) said Monday that Health Canada has approved the company's Esprit BTK Everolimus Eluting Resorbable Scaffold System for treating people with chronic limb-threatening ischemia below the knee.

The system is designed to keep arteries open while delivering the drug everolimus to support vessel healing before completely dissolving, the company said.

Abbott said clinical data showed that the dissolving stent improves patient outcomes and reduces repeat procedures by 48% compared to balloon angioplasty.